Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said its partner Inretio Inc, a leading Israeli medical device startup and developer of the PREVA novel clot removal device for ischemic stroke treatment, is moving into a new facility of its own in Sapirim Industrial Park, Israel.
Therma Bright has invested in Inretio and its PREVA clot removal device, the company noted in a statement.
Inretio’s new development site will feature a large manufacturing floor and a cleanroom which will allow the company to design, develop, and manufacture its PREVA stroke treatment, Therma Bright said.
READ: Therma Bright appoints inhaled drug pioneer Dr John Patton as chairman of InStatin
It is designed to scale production of the PREVA device up to 5,000 units per month, whereas the previous space had a maximum production capacity of 500 units per month.
"This expansion into a new space with the right equipment to bring this innovative, leading-edge ischemic stroke solution to market faster is fully supported by Therma Bright," commented Therma Bright CEO Rob Fia.
"With initial tests wrapping up and preparation for human trial approval and clinical study, the new site offers the right environment for the Inretio team's success."
Inretio CEO Raviv Vine added: "Having our own manufacturing facility is a game-changer for us. It will enable us to produce our PREVA device at scale, which is critical as we move towards clinical trials and potential commercialization."
Therma Bright is a developer and partner in a range of leading-edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie